publication . Article . 2014

Somatostatin-based Radiopeptide Therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in Neuroendocrine Tumors

Romer A Seiler D Marincek N Brunner P Koller MT Ng QK Maecke HR Muller-Brand J Rochlitz C B;
Closed Access
  • Published: 01 Jan 2014 Journal: Eur J Nucl Med Mol Imaging, volume 41, issue 2, pages 214-222
Abstract
PURPOSE: Somatostatin based radiopeptide treatment is generally performed using the ß emitting radionuclides (90)Y or (177)Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. METHODS: In a comparative cohort study patients with advanced neuroendocrine tumours underwent repeated cycles of [(90)Y DOTA] TOC or [(177)Lu DOTA] TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. RESULTS: Overall 910 patients underwent 1804 cycles of [(90)Y DOTA] TOC and 141 patients...
Subjects
mesheuropmc: neoplasms
Funded by
SNSF| Somatostatin-coupled Nanoparticles for Cancer Imaging and Therapy
Project
  • Funder: Swiss National Science Foundation (SNSF)
  • Project Code: PZ00P3_145303
  • Funding stream: Careers | Ambizione
,
SNSF| Somatostatin-coupled Nanoparticles for Cancer Imaging and Therapy
Project
  • Funder: Swiss National Science Foundation (SNSF)
  • Project Code: PZ00P3_126616
  • Funding stream: Careers | Ambizione
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2014

Somatostatin-based Radiopeptide Therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in Neuroendocrine Tumors

Romer A Seiler D Marincek N Brunner P Koller MT Ng QK Maecke HR Muller-Brand J Rochlitz C B;